Marketing during a product recall: what to pull and say

A med spa promotes a skincare device on its home page the same week the maker sends a correction notice for it. A chiropractic clinic has a supplement in its online shop and an email campaign about it scheduled for Friday when the supplier announces a recall of two lots. A DME supplier runs search ads for a monitor that the manufacturer is pulling back from the field. A health company that sells a private-label product under its own name learns of a defect from customer complaints. In each case the marketing keeps running on its own schedule unless someone stops it, and every ad, page and message still says the product is available and works.

This guide reads FDA’s recall rules at 21 CFR Part 7 and its device correction and removal rules at 21 CFR Part 806, the FTC Act’s ban on deceptive practices, and the HIPAA provisions that apply when a practice contacts patients about a recalled product. It covers what to pull, what to say and to whom, and what to keep on file. Refunds and replacements under a written warranty are covered in our health product warranty rules guide, shipping delays and refunds on mail and online orders in the FTC mail order rule for health products, and hearing devices in OTC hearing aid advertising rules. For selling products from the office, see selling supplements in a medical practice and DME supplier marketing.

The short version

• Stop the marketing first. FDA’s guidance says a recall communication tells recipients that further distribution or use of remaining product should cease immediately (21 CFR 7.49(a)(2)). Ads, product pages, scheduled emails and social posts that keep selling the product work against that instruction.
• A practice that bought, sold or used the product is a consignee. 21 CFR 7.3(n) defines a consignee as anyone who received, purchased, or used the recalled product, and 7.49(d) says consignees should immediately carry out the recalling firm’s instructions and, where necessary, pass the recall on to their own customers.
• Do not turn the notice into a promotion. 7.49(c)(2) says a recall communication should not contain promotional materials or any other statement that may detract from the message.
• Use the firm’s and FDA’s words for the facts. The FTC Act declares unfair or deceptive acts or practices in or affecting commerce unlawful (15 USC 45(a)(1)). Saying more or less than the notice says about the hazard, the affected lots or the fix creates a claim you would have to support.
• Private label can make you the manufacturer. Under 21 CFR 806.2(h), a person who relabels a device or initiates its specifications for a second party to make counts as a manufacturer for Part 806, with its reporting and record duties.
• HIPAA allows recall work, not recall marketing. 45 CFR 164.512(b)(1)(iii)(C) permits disclosures to an FDA-regulated firm to enable product recalls, including locating and notifying people who received the product. A message that encourages buying a replacement product is a different question under 164.501 and 164.508(a)(3).

Recall, correction, withdrawal: what the notice is telling you

The words in a supplier’s notice have defined meanings, and the meaning tells you how much of your marketing has to change. 21 CFR 7.3 sets them for FDA-regulated products generally, and 21 CFR 806.2 sets parallel terms for devices.

• Recall (7.3(g)) is a firm’s removal or correction of a marketed product that FDA considers to be in violation of the laws it administers and against which the agency would initiate legal action, such as seizure.
• Correction (7.3(h)) is repair, modification, adjustment, relabeling, destruction, or inspection, including patient monitoring, of a product without physically removing it. For devices, 806.2(d) uses the same list and says without its physical removal from its point of use. Removal (806.2(j)) is the physical removal of a device from its point of use to another location for those purposes.
• Market withdrawal (7.3(j)) is a removal or correction that involves a minor violation FDA would not take legal action on, or no violation at all, such as normal stock rotation.
• Stock recovery (7.3(k)) covers product that never left the firm’s direct control. If you never received it, there is nothing for your marketing to change.

FDA also classifies each recall by health hazard (7.3(m)). Class I is a situation with a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. Class II is where use or exposure may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. Class III is where use or exposure is not likely to cause adverse health consequences. Quote the class FDA assigned; do not supply one yourself, and do not describe a Class I recall in Class III terms to calm patients down.

A recall can be the firm’s own decision or come at FDA’s request (7.40(b), 7.45, 7.46). Either way, 7.50 says FDA lists each new recall in its weekly Enforcement Report, and FDA’s recalls page says not every recall gets a press release or appears on that page. So the notice from your supplier may reach you before anything public does. 7.50 also says FDA will intentionally delay public notification of recalls of certain drugs and devices where public notice may cause unnecessary and harmful anxiety and initial consultation between patients and their physicians is essential. If a device or drug notice tells clinicians to contact patients first, do that before anything goes on social media.

What to pull, and where it hides

The recalling firm decides how deep the recall goes: to the consumer or user level, the retail level or the wholesale level (7.42(b)(1)). If your practice or company is in that chain, the instruction to stop distribution or use (7.49(a)(2)) covers your sales. Marketing is how the sales happen, so it stops with them. The places to check:

• Paid ads. Search, Shopping and social campaigns, including ads that name the product only in a sitelink, extension or image. Pause them; do not delete them, because the record of what ran and when may be needed.
• Your website. Product pages, the online shop, “products we use” pages, service pages that name the device, blog posts and comparison pages. Take the buy button down or mark the item unavailable and point to the notice.
• Scheduled and automated messages. Email campaigns, text promotions, review requests after a purchase, reorder reminders and abandoned-cart emails. These are the ones teams forget, because nobody sends them by hand.
• Social and video. Pinned posts, story highlights, short videos and live replays that demonstrate or recommend the product, including posts by staff and by creators you pay. Our healthcare influencer marketing guide covers paid creators.
• Listings and feeds. Marketplace listings, product feeds to ad platforms, and any directory or booking profile that names the product as a service.
• People and scripts. Front desk scripts, call center and chat answers, and any AI front desk prompt that offers the product. Tell staff what to say if a patient asks.
• Print and in-office. Brochures, shelf signs, displays and waiting room screens.

A correction that does not remove the product may not require pulling every mention, but any claim the correction touches has to go. If the firm is relabeling a device to add a warning or change instructions, your page cannot keep the old instructions or a claim the new labeling no longer supports. Our medical device marketing claims guide covers how device claims connect to what the device is cleared or approved for.

What to say, and to whom

For FDA-regulated products, the recalling firm owns the recall communication. 7.49(c) says it should be brief, identify the product, size, lot numbers, codes or serial numbers, explain the reason and the hazard, give specific instructions, and give a ready way for recipients to report whether they have the product. When you pass the recall on to your own patients or customers, as 7.49(a)(3) and (d) contemplate where the firm’s instructions call for it, the same qualities make a good notice: the product and lots, what the firm says the problem is, what to do, and how to reach you.

Three rules keep a practice or company notice honest:

1. Use the source’s facts. Quote or link the firm’s notice and FDA’s entry. Do not estimate risk, add a cause the notice does not state, or say the problem is “minor” or “precautionary” unless the notice says so. The FTC Act’s ban on deceptive acts or practices in 15 USC 45(a) applies to what you say about the recall as much as to the original ad.
2. Keep it free of selling. 7.49(c)(2) says the recall communication should not contain irrelevant qualifications, promotional materials, or any other statement that may detract from the message. A coupon, an upsell to a premium alternative or a “book now” banner on a safety notice does exactly that.
3. Say what the patient should do clinically. If the product was used in treatment or is an implant or worn device, the patient question is clinical, not commercial: whether to stop using it and whether to be seen. That comes from the clinician, following the firm’s and FDA’s instructions.

Public warnings are a separate step. Under 7.42(b)(2), a public warning is reserved for urgent situations where other means of preventing use appear inadequate, and FDA, in consultation with the recalling firm, will ordinarily issue it. A recalling firm that decides to issue its own public warning is requested to submit it and its distribution plan to FDA for review and comment. A practice posting on its own social accounts is not the recalling firm, but the same caution applies: link to the official notice rather than writing your own version of the hazard.

Patient notices and HIPAA

A practice that sold or administered a recalled product may need to find the patients who received it. HIPAA permits a covered entity to disclose protected health information, without authorization, to a person subject to FDA jurisdiction for an FDA-regulated product it is responsible for, for activities related to that product’s quality, safety or effectiveness. 45 CFR 164.512(b)(1)(iii)(C) names enabling product recalls, repairs, or replacement, or lookback, including locating and notifying individuals who have received products that have been recalled, withdrawn, or are the subject of lookback.

The line to watch is marketing. 45 CFR 164.501 defines marketing as a communication about a product or service that encourages recipients to purchase or use it, with exceptions for treatment and certain health care operations communications, which are lost when the covered entity receives financial remuneration from a third party whose product is being described. Under 164.508(a)(3), using or disclosing protected health information for marketing requires the patient’s authorization, apart from face-to-face communications and promotional gifts of nominal value, and if a third party pays the covered entity, the authorization must say so. A notice that tells a patient their product is recalled and what to do is a safety communication. A message that goes on to promote a replacement from a manufacturer that pays the practice for the mailing needs to be checked against those sections before it goes out. Our guide to HIPAA marketing rules covers authorizations in more depth.

If you are the manufacturer: private label and devices

A health company or practice that sells a product under its own name should check whether it is the recalling firm. For FDA-regulated products generally, 7.3(i) defines the recalling firm as the one that initiates the recall or, in an FDA-requested recall, the firm with primary responsibility for the manufacture and marketing of the product. For devices, 806.2(h) says a manufacturer includes a person who repackages or changes the container, wrapper, or labeling of a device in its distribution, and a person who initiates specifications for devices manufactured by a second party for subsequent distribution by the person initiating them.

A device manufacturer or importer that initiates a correction or removal to reduce a risk to health, or to remedy a violation that may present a risk to health, must report it to FDA in writing within 10 working days of initiating it (806.10(a)-(b)), unless an exemption applies. The report includes a copy of all communications about the correction or removal and the names and addresses of their recipients (806.10(c)(12)), so the notices your marketing team sends become part of the regulatory file. Corrections and removals that do not have to be reported still need a record, kept for 2 years beyond the expected life of the device (806.20). 806.10(e) says a report does not necessarily reflect a conclusion that it is an admission that the device caused or contributed to a death or serious injury.

For any product, 7.46(a) says a firm that removes or corrects a distributed product because it believes the product is violative is requested to notify the appropriate FDA district office immediately, and lists what FDA will ask for, including a copy of the recall communication or the proposed one and the proposed strategy.

Restarting the marketing

A recall ends when FDA terminates it: 7.55 says that happens when FDA determines that all reasonable efforts have been made to remove or correct the product under the recall strategy, and FDA’s district office issues written notification of termination to the recalling firm. A correction may end sooner for your stock, once your units are repaired, relabeled or replaced. Before ads and pages come back:

• Confirm in writing from the firm that the units you will sell or use are not affected, or are corrected, and keep that with the campaign file.
• Rewrite any claim the recall touched. If the problem was a labeling error or a missing warning, the new page follows the new labeling.
• Do not advertise the recall as a selling point. “Now safer” or “new and improved after the recall” is a claim about safety that needs support like any other.
• Do not reuse old reviews or testimonials that describe the affected version as if they were about the corrected one.
• Restart reminders and reorder emails only for products and customers that the notice no longer covers.

Competitor recalls

When a rival’s product is recalled, the temptation is to advertise against it. 15 USC 45(a) applies to comparative claims as to any other: a claim that your product is safer, or that patients of another practice are at risk, needs the same support as any safety claim. The recall notice supports what it says about the recalled product and the listed lots; it says nothing about your product. An informational post that links the official notice and tells patients to contact the practice that treated them is a service to the public. An ad that uses the notice to imply your alternative has no such risk is a claim you would have to prove. See our guide to comparative advertising that names competitors.

Prepare before it happens

21 CFR 7.59 lists steps FDA suggests firms take in advance: a current written contingency plan for recalls, product coding that allows positive lot identification, and distribution records kept long enough to find recalled product, for a period that exceeds the product’s shelf life and expected use. A practice that sells or uses products can keep a smaller version:

1. Know what you sell and use. A list of products and devices, with supplier and the lot or serial numbers you received.
2. Know who got it. Sales and dispensing records linked to lot numbers, so a two-lot recall means two lists, not every customer.
3. Subscribe at the source. FDA offers an email signup for its recalls, market withdrawals and safety alerts list. Supplier notices go to a named person, not a shared inbox nobody reads.
4. Map your marketing. One sheet that lists every campaign, page, feed, automation and script that names each product, so pausing takes minutes.
5. Write the notice template now. Product, lots, the firm’s stated reason, what to do, who to call, a link to the official notice, no offers.
6. Keep the file. What ran, when it stopped, the notices sent and to whom. Our advertising records guide covers retention.

Use and avoid

• Use: “The maker has recalled lots [numbers] of this product. Stop using it and call us at [office number]. The official notice is here: [link].” Avoid: “Out of an abundance of caution, a small number of units are being updated.” unless the notice says that.
• Use: “This item is unavailable while the manufacturer’s recall is under way.” on the product page. Avoid: a live buy button with a recall note at the bottom.
• Use: a plain safety notice with no offer. Avoid: “Affected? Save on our upgraded model.” in the same message.
• Use: FDA’s class as FDA stated it. Avoid: calling a Class I recall “minor” or “routine”.
• Use: a link to the official competitor notice for public information. Avoid: “Unlike [competitor], ours is safe.”

An illustration

This is a made-up example, not a client. A med spa sells a home-use skincare device and uses a professional version in treatments. The maker sends a correction notice for the home units: a labeling change that adds a warning and removes one listed use. The notice does not recall the professional version.

The fix: the home device page drops the removed use and adds the new warning, the shop marks it unavailable until corrected units arrive, the scheduled email promoting it is paused, and customers who bought the affected units get a short notice with the maker’s instructions and a link to the official notice. The service pages for the professional treatment stay up, because the notice does not cover that device, and staff get a two-line answer for patients who ask whether the treatment is affected. Nothing in the notice to customers offers a discount on the professional treatment.

How we help

We build and maintain practice websites, run Google Ads and lead generation campaigns, and set up an AI front desk for independent practices, and we can map which pages, campaigns and scripts name each product so a pause is quick when a notice arrives. We are not a law firm and do not give legal or medical advice; the recall itself is run by the recalling firm under FDA’s oversight. Related guides: healthcare email marketing and our guide to healthcare marketing rules.

Sources

• 21 CFR Part 7: Enforcement Policy (Subpart C, Recalls)
• 21 CFR Part 806: Medical Devices; Reports of Corrections and Removals
• 15 USC 45: Unfair methods of competition unlawful; prevention by Commission
• 45 CFR Part 164: sections 164.501, 164.508(a)(3) and 164.512(b)(1)(iii)
• FDA: Recalls, Market Withdrawals, & Safety Alerts

More in Health companies, vendors and employers